Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
Primary Purpose
Dystonia, Movement Disorder
Status
Unknown status
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
deep brain stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Dystonia focused on measuring deep brain stimulation, pallidum, tardive dystonia, randomized, double blind, multicenter
Eligibility Criteria
Inclusion Criteria: Operational criteria for tardive dystonia for > 18 months after cessation of neuroleptic exposure 18-75 years Relevant functional impairment in daily living activities BFMDRS > 8 or AIMS > 16 Informed written consent Exclusion Criteria: PANNS >60 (Schizophrenia) Hamilton-Score > 18 (Depression) MATTIS-Score <120 (Dementia) Preceding stereotactic neurosurgery Pronounced brain atrophy Increased bleeding risk Decreased immune status Botulinum Toxin treatment within the last 3 months
Sites / Locations
- Andreas KupschRecruiting
Arms of the Study
Arm 1
Arm Type
Placebo Comparator
Arm Label
1
Arm Description
device
Outcomes
Primary Outcome Measures
Improvement of the motor scale of Burke-Fahn-Marsden-Dystonia Rating Scale via blinded video assessment 3 months after starting DBS in comparison to sham-stimulated patients
Secondary Outcome Measures
AIMS
Non-motor subscores of BMFDRS
Visual analogue scales for both patients and treating physicians
Quality of life (SF-36)
Psychiatric assessment (HADS-D and PANSS)
Full Information
NCT ID
NCT00331669
First Posted
May 26, 2006
Last Updated
March 3, 2009
Sponsor
Charite University, Berlin, Germany
Collaborators
Humboldt-Universität zu Berlin, Ruhr University of Bochum, Medical University of Cologne, Heinrich-Heine University, Duesseldorf, University Hospital Freiburg, Medical University of Hannover, Medical University Innsbruck, University of Kiel, Philipps University Marburg Medical Center, Ludwig-Maximilians - University of Munich, University of Rostock, University of Regensburg, University Hospital Tuebingen, Medical University of Vienna, Medtronic
1. Study Identification
Unique Protocol Identification Number
NCT00331669
Brief Title
Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
Official Title
Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia
Study Type
Interventional
2. Study Status
Record Verification Date
February 2009
Overall Recruitment Status
Unknown status
Study Start Date
May 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Charite University, Berlin, Germany
Collaborators
Humboldt-Universität zu Berlin, Ruhr University of Bochum, Medical University of Cologne, Heinrich-Heine University, Duesseldorf, University Hospital Freiburg, Medical University of Hannover, Medical University Innsbruck, University of Kiel, Philipps University Marburg Medical Center, Ludwig-Maximilians - University of Munich, University of Rostock, University of Regensburg, University Hospital Tuebingen, Medical University of Vienna, Medtronic
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this randomized, double blind, multi-center study is to assess the efficacy and safety of bilateral pallidal deep brain stimulation in patients with tardive dystonia.
Detailed Description
Deep brain stimulation (DBS) has been established as a new reversible, neurosurgical therapeutic option for patients suffering from disabling neurological movement disorders such as essential tremor and Parkinson´s disease. Recently, deep brain stimulation has been successfully applied in patients with primary generalized and segmental dystonia. Additionally, a number of case reports suggest that pallidal deep brain stimulation may also improve tardive dystonia, which may for instance result from the intake of neuroleptics and which is notoriously difficult to treat medically. The present study will investigate the effects of pallidal DBS using a double blind, randomized design (sham- versus verum-stimulation within a 3-months interval post implantation of the electrodes).
Initially 60 patients had been calculated in a power analysis to assess significant results based on an average improvement of dystonic symptoms of 30%. However, in a recent study (Damier et al., Archives of General Psychiatry, 2007), 10 out of 10 showed a successful outcome of approximately 50% decrease on the extrapyramidal symptoms rating scale score. The exact one- sided lower 95% confidence limit would be 0.794 for this result. If such an approach is chosen for sample size estimation with 18 verum and 18 placebo patients one would obtain a power of 82% against a placebo effect of 30% success rate. For a placebo effect of 25% one needs 16+16 patients and for the placebo effect of 20% one needs 12+12 patients. We thus decided to reduce the sample size to 36- 32- 24 patients. It is expected that the continuous primary outcome measure will preserve even higher power than the binary one used in the study mentioned above. The local ethical committee has approved this.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dystonia, Movement Disorder
Keywords
deep brain stimulation, pallidum, tardive dystonia, randomized, double blind, multicenter
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Placebo Comparator
Arm Description
device
Intervention Type
Procedure
Intervention Name(s)
deep brain stimulation
Intervention Description
high frequency stimulation
Primary Outcome Measure Information:
Title
Improvement of the motor scale of Burke-Fahn-Marsden-Dystonia Rating Scale via blinded video assessment 3 months after starting DBS in comparison to sham-stimulated patients
Time Frame
3 months
Secondary Outcome Measure Information:
Title
AIMS
Time Frame
3 months
Title
Non-motor subscores of BMFDRS
Time Frame
3 months
Title
Visual analogue scales for both patients and treating physicians
Time Frame
3 months
Title
Quality of life (SF-36)
Time Frame
3 months
Title
Psychiatric assessment (HADS-D and PANSS)
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Operational criteria for tardive dystonia for > 18 months after cessation of neuroleptic exposure
18-75 years
Relevant functional impairment in daily living activities
BFMDRS > 8 or AIMS > 16
Informed written consent
Exclusion Criteria:
PANNS >60 (Schizophrenia)
Hamilton-Score > 18 (Depression)
MATTIS-Score <120 (Dementia)
Preceding stereotactic neurosurgery
Pronounced brain atrophy
Increased bleeding risk
Decreased immune status
Botulinum Toxin treatment within the last 3 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andreas R Kupsch, MD, PhD
Phone
xx49-30-450-50
Ext
660103
Email
andreas.kupsch@charite.de
First Name & Middle Initial & Last Name or Official Title & Degree
Andrea Kuehn, MD
Phone
xx49-30-450-50
Ext
660203
Email
andrea.kuehn@charite.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas R Kupsch, MD
Organizational Affiliation
Dpt. of Neurology, Augustenburger Platz 1, 13353 Berlin, Charite, Campus Virchow, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Andreas Kupsch
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas R Kupsch, MD, PhD
Phone
xx49-30-450-50
Ext
660103
Email
andreas.kupsch@charite.de
First Name & Middle Initial & Last Name & Degree
Andrea Kuehn, MD
Phone
xx49-30-450-50
Ext
660203
Email
andrea.kuehn@charite.de
First Name & Middle Initial & Last Name & Degree
Andreas R Kupsch, MD, PhD
12. IPD Sharing Statement
Citations:
PubMed Identifier
15668437
Citation
Trottenberg T, Volkmann J, Deuschl G, Kuhn AA, Schneider GH, Muller J, Alesch F, Kupsch A. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology. 2005 Jan 25;64(2):344-6. doi: 10.1212/01.WNL.0000149762.80932.55.
Results Reference
background
PubMed Identifier
15871516
Citation
Franzini A, Marras C, Ferroli P, Zorzi G, Bugiani O, Romito L, Broggi G. Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases. J Neurosurg. 2005 Apr;102(4):721-5. doi: 10.3171/jns.2005.102.4.0721.
Results Reference
background
PubMed Identifier
17283284
Citation
Damier P, Thobois S, Witjas T, Cuny E, Derost P, Raoul S, Mertens P, Peragut JC, Lemaire JJ, Burbaud P, Nguyen JM, Llorca PM, Rascol O; French Stimulation for Tardive Dyskinesia (STARDYS) Study Group. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007 Feb;64(2):170-6. doi: 10.1001/archpsyc.64.2.170.
Results Reference
background
PubMed Identifier
30249417
Citation
Gruber D, Sudmeyer M, Deuschl G, Falk D, Krauss JK, Mueller J, Muller JU, Poewe W, Schneider GH, Schrader C, Vesper J, Volkmann J, Winter C, Kupsch A, Schnitzler A; DBS study group for dystonia. Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial. Brain Stimul. 2018 Nov-Dec;11(6):1368-1377. doi: 10.1016/j.brs.2018.08.006. Epub 2018 Sep 11.
Results Reference
derived
Learn more about this trial
Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
We'll reach out to this number within 24 hrs